The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN)
Abstract
BACKGROUND: The literature investigating pancreatic invasive intraductal papillary mucinous neoplasm (IPMN) has largely come from small institutional studies, preventing adequately powered comparisons of adjuvant therapy versus surgery alone (SA) within specific patient subgroups.METHODS: Patients with resected, stage I through IV, invasive IPMN and conventional pancreatic ductal adenocarcinoma (PDAC) were identified in the National Cancer Data Base (1998‐2010). Cox modeling of patients with invasive IPMN was used to compare overall survival (OS) between patients who received adjuvant therapy and those who underwent SA. A second model was used to compare OS between patients with invasive IPMN and those with PDAC.RESULTS: For the 1220 patients with invasive IPMN, the median OS was 28.9 months; the 1‐year and 5‐year actuarial survival rates were 76% and 17%, respectively; and 47% received adjuvant therapy. Cox modeling associated SA with worse OS (hazard ratio, 1.36; 95% confidence interval, 1.17‐1.58; P = .00005) as well as American Joint Committee on Cancer (AJCC) TNM stage III/IV disease, positive lymph node status, positive margins, and poor tumor differentiation (all P ≤ .05). In addition, Cox modeling stratified by the following characteristics demonstrated improved OS with adjuvant therapy: AJCC TNM stage II or III/IV, positive lymph node status, positive margins, and poorly differentiated tumors. There was no survival advantage from adjuvant therapy for patients who had AJCC TNM stage I or lymph node‐negative disease. Patients who had invasive IPMN had improved risk‐adjusted OS compared with those who had PDAC (hazard ratio, 0.73; 95% confidence interval, 0.68‐0.78; P < .00001).CONCLUSIONS: Invasive IPMN appears to be more indolent than conventional PDAC. Adjuvant therapy is associated with improved OS compared with SA in patients with invasive IPMN, especially for those with higher stage disease, positive lymph nodes, positive margins, or poorly differentiated tumors. Conversely, this benefit does not extend to patients with stage I or lymph node‐negative disease. Cancer 2016;122:521–533. © 2015 American Cancer Society.Keywords
This publication has 15 references indexed in Scilit:
- Pathohistological Subtype Predicts Survival in Patients With Intraductal Papillary Mucinous Neoplasm (IPMN) of the PancreasAnnals of Surgery, 2013
- Adjuvant Radiotherapy in the Treatment of Invasive Intraductal Papillary Mucinous Neoplasm of the Pancreas: an Analysis of the Surveillance, Epidemiology, and End Results RegistryAnnals of Surgical Oncology, 2011
- Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypesGut, 2011
- Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinomaCancer, 2010
- Histopathologic Basis for the Favorable Survival after Resection of Intraductal Papillary Mucinous Neoplasm-Associated Invasive Adenocarcinoma of the PancreasAnnals of Surgery, 2010
- Adjuvant Chemoradiotherapy After Pancreatic Resection for Invasive Carcinoma Associated With Intraductal Papillary Mucinous Neoplasm of the PancreasInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Intraductal Papillary Mucinous NeoplasmsAnnals of Surgery, 2007
- Impact of Resection Status on Pattern of Failure and Survival After Pancreaticoduodenectomy for Pancreatic AdenocarcinomaAnnals of Surgery, 2007
- 1423 Pancreaticoduodenectomies for Pancreatic Cancer: A Single-Institution ExperienceJournal of Gastrointestinal Surgery, 2006
- Long-Term Survival After Curative Resection for Pancreatic Ductal AdenocarcinomaAnnals of Surgery, 1996